AXSOME THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
AXSOME THERAPEUTICS, INC. (AXSM) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $89.06 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-02-23
- AXSOME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $92.48, a 41.21% increase year-over-year.
- AXSOME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $65.49, a 27.31% increase year-over-year.
- AXSOME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $51.44, a 144.95% increase year-over-year.
- AXSOME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $21.00, a 57.37% decline year-over-year.
- AXSOME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $89.06, a 37.27% increase from fiscal 2024.
- AXSOME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $64.88, a 22.25% increase from fiscal 2023.
- AXSOME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $53.07, a 88.33% increase from fiscal 2022.
- AXSOME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $28.18, a 28.91% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2025-12-31 | $89.06 10-K · filed 2026-02-23 | |||
| 2025-09-30 | $88.37 10-Q · filed 2025-11-03 | |||
| 2025-06-30 | $89.21 10-Q · filed 2025-08-04 | |||
| 2025-03-31 | $92.48 10-Q · filed 2025-05-05 | |||
| 2024-12-31 | $64.88 10-K · filed 2026-02-23 | |||
| 2024-09-30 | $64.54 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $64.42 10-Q · filed 2024-08-05 | |||
| 2024-03-31 | $65.49 10-Q · filed 2024-05-06 | |||
| 2023-12-31 | $53.07 10-K · filed 2026-02-23 | |||
| 2023-09-30 | $53.38 10-Q · filed 2023-11-06 | |||
| 2023-06-30 | $52.18 10-Q · filed 2023-08-07 | |||
| 2023-03-31 | $51.44 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $28.18 10-K · filed 2025-02-18 | |||
| 2022-09-30 | $28.07 10-Q · filed 2022-11-07 | |||
| 2022-06-30 | $23.70 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $21.00 10-Q · filed 2022-05-02 | |||
| 2021-12-31 | $39.64 10-K · filed 2024-02-23 | |||
| 2021-09-30 | $45.81 10-Q · filed 2021-11-08 | |||
| 2021-06-30 | $48.74 10-Q · filed 2021-08-09 | |||
| 2021-03-31 | $49.26 10-Q · filed 2021-05-10 | |||
| 2020-12-31 | $36.77 10-K · filed 2023-02-28 | |||
| 2019-12-31 | $12.49 10-K · filed 2022-03-01 | |||
| 2018-12-31 | $1.99 10-K · filed 2021-03-01 | |||
| 2017-12-31 | $3.06 10-K · filed 2020-03-12 | |||
| 2016-12-31 | $5.13 10-K · filed 2019-03-15 | |||
| 2015-12-31 | $4.21 10-K · filed 2018-03-07 | |||
| 2014-12-31 | $2.05 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |